Citations

Clear

421 citation(s) found for "Short, C".

Accuracy of Computer-Assisted Navigation in Total Ankle Arthroplasty Surgery Using Computed Tomography: A Short Report
Rakauskas, Taylor R , Adam, Henderson , Meli, Gabrielle M , Herbel, Cole , El Masry, Seif , Boux De Casson, François , Haupt, Edward

Mayo Clinic

Foot & Ankle International | October 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10711007261497273 | PMID 42960558 Get It

Background: Computer-assisted navigation (CAN) offers dynamic intraoperative guidance in total ankle arthroplasty (TAA). Although laboratory data suggest superior precision, in vivo evidence is lacking. This study used weightbearing computed tomography (WBCT) to evaluate CAN accuracy of postoperative TAA implant position relative to the plan. We hypothesized that absolute discrepancies would be <3 mm or <3°. Methods: Thirteen consecutive patients (November 2024–November 2025) underwent TAA using CAN. Preoperative computed tomography–based 3D models were used for templating. Postoperative WBCT scans were used to measure final implant seating, and computerized measurements were used to identify implant placement discrepancy. We analyzed absolute discrepancies between planned vs final postoperative positions. Results: Tibial absolute discrepancies were within desired limits for varus/valgus (1.65° ± 1.43°), slope (1.87° ± 1.34°), and cut height (0.68 ± 0.62 mm) but not for axial rotation (3.97 ± 2.64). For the talus, varus/valgus (2.93° ± 1.86°) and cut height (0.66 ± 0.71 mm) absolute discrepancies were within desired limits. The increased talar slope deviation (3.90 ± 2.89) in the final position may be due to non-navigated implant impaction. Conclusion: Although discrepancies persisted in tibial rotational alignment and talar positioning, the low variability across measurements suggests that CAN may support accurate implant positioning. These short-term positioning accuracy findings support the utility of CAN as a potential tool for enhancing implant positioning reproducibility in TAA. Level of Evidence: Level IV, case series.
Falling short: Inadequate target attainment in guideline-based therapy of nontuberculous mycobacterial disease
Dick, Thomas , Dartois, V , Pienaar, Elsje

Mayo Clinic

No container title available | September 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.24.26363927 | PMID 42818340 Get It

Nontuberculous mycobacterial (NTM) infections are a scourge that affect growing patient populations due to the rise of risk factors associated with these opportunistic pathogens. Cure rates are unacceptably low despite intensive multidrug and multi-year therapy. The issue of poor drug exposure relative to inferior potency of repurposed antibiotics against NTM pathogens is broadly recognized as a major factor underlying dismal success rates. Yet, a quantitative and systematic evaluation of probabilities of pharmacokinetic-pharmacodynamic (PK-PD) target attainment (PTA) is lacking. Here, we leveraged published population PK models and minimum inhibitory concentration distributions across large patient populations to generate PTAs for standard of care antibiotics used in the treatment of NTM infections. PTAs of tuberculosis drugs were included in our analysis as a baseline since tuberculosis cure rates are excellent compared to NTM diseases. We found that PK-PD target attainment for NTM was low overall and that PTAs were generally consistent with reported clinical outcomes. Specifically, drugs for which genetic resistance is associated with worse outcome showed favorable PTAs, consistent with their contribution to cure. These include macrolides for M. abscessus and the M. avium complex (MAC), and rifampicin for M. kansasii. Bedaquiline emerged as a promising option against M. abscessus and MAC, and clofazimine against the latter, consistent with recent clinical reports. Omadacycline PTAs predict improved efficacy compared to tigecycline for patients with M. abscessus and suggest clinical utility for MAC. As is common practice for antibacterials, PTA considerations could inform NTM treatment guidelines and help select drug combinations in future trials.
Intratunnel Anchor Fixation and Transtibial Pull‐Through Repair Show Comparable Short‐Term Outcomes After Meniscus Root Repair: A Propensity‐Matched Comparative Study
Tagliero, Adam J. , Ahmad, Rana A. , Mikula, Jacob D. , Hevesi, Mario, Smith, Patrick A. , Krych, Aaron J. , Krych, Aaron J , Tagliero, Adam

Mayo Clinic

Arthroscopy | September 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/arj.70601 | PMID 42782213 Get It

Purpose To compare short‐term outcomes of intratunnel anchor fixation versus transtibial pull‐through repair for meniscus root tears with a minimum of 12‐month follow‐up. Methods Patients who underwent primary meniscus root repair between 2011 and 2024 at a single institution were retrospectively reviewed. Inclusion criteria consisted of primary medial or lateral meniscus root repair using either intratunnel anchor fixation or transtibial pull‐through repair, availability of preoperative radiographs, and completion of postoperative patient‐reported outcome measures with a minimum of 12‐month follow‐up. The groups were propensity‐matched by age, sex, body mass index, operative side, root laterality, and concomitant procedures. Baseline radiographic characteristics (hip‐knee‐ankle angle and posterior tibial slope) were measured. Outcomes included Lysholm score, International Knee Documentation Committee score, Tegner activity score (preoperative and postoperative), Visual Analog Scale for pain at rest and with activity, satisfaction, subjective surgical outcome, and reoperations. Results Fifty patients who underwent intratunnel anchor fixation (mean age, 44 years) were propensity‐matched to 100 patients who underwent transtibial pull‐through repair (mean age, 41 years). Mean follow‐up was 1.5 years (range, 1.0‐2.3) in the intratunnel anchor group and 6.1 years (range, 2.7‐13.7) in the transtibial pull‐through group. Reoperation rates were 8% and 14%, respectively ( P = .43), with repair failure occurring in 4% and 6% ( P > .99). Preoperative and postoperative Tegner scores were similar between groups. Tegner minimal clinical important difference was 0.8, and 26.5% of intratunnel anchor patients achieved this compared with 0% of transtibial pull‐through patients. Patients in the intratunnel anchor cohort reported slightly lower Visual Analog Scale pain with activity (1.8 vs 2.5, P = .02). Postoperative Lysholm (87 vs 83, P = .05) and International Knee Documentation Committee scores (79 vs 76, P = .09) were comparable between groups. A greater proportion of intratunnel anchor patients achieved Patient Acceptable Symptomatic State compared with transtibial pull‐through patients for Visual Analog Scale with activity (74% vs 56%, P = .03) and Lysholm (66% vs 47%, P = .01). Most patients in both cohorts rated their outcome as “much better” or “slightly better” ( P = .49), and satisfaction scores were high. Conclusions At short‐term follow‐up, both the intratunnel anchor and transtibial pull‐through techniques showed high patient satisfaction and comparable overall clinical outcomes. There were no differences in reoperation rates between techniques. Level of Evidence Level III, retrospective comparative case series.
Short Term Safety and Effectiveness of Valganciclovir Prophylactic Dosing for Cytomegalovirus in Solid Organ Transplant Recipients Requiring Intermittent Hemodialysis
Edwards, Megan , Sturm, Ashley , Shulha, Jenny , Mara, Kristin C. , Mahmood, Maryam, Glauner, Lanea, Mara, Kristin C , Edwards, Megan E , Mahmood, Maryam , Glauner, L.

Mayo Clinic

Transplant Infectious Disease | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/tid.70317 | PMID 42717241 Get It

ABSTRACT Background Valganciclovir is the preferred antiviral agent for cytomegalovirus (CMV) prophylaxis in solid organ transplant (SOT) recipients; however, limited data exist to guide optimal dosing in patients requiring intermittent hemodialysis (iHD). This study evaluated the safety and efficacy of our institution's current dosing strategy of valganciclovir 450 mg three times weekly. Methods In this single‐center, retrospective study, adult liver, heart, lung, and kidney transplant recipients from January 2014 to November 2024 were included. Patients requiring ≥ 3 iHD sessions posttransplant and receiving valganciclovir 450 mg three times weekly were compared with recipients with normal renal function receiving 900 mg once daily. The primary outcomes were the risk of neutropenia, leukopenia, and thrombocytopenia within 3.5 months posttransplant. Results A total of 116 patients were included in the iHD cohort and were matched 1:2 to 232 patients in the normal renal function cohort. Rates of leukopenia and neutropenia were comparable between cohorts. However, thrombocytopenia occurred significantly more frequently in the iHD cohort (45.2% vs. 26.7%; p = 0.002). No significant differences were observed in rates of CMV infection between groups. Conclusion Valganciclovir 450 mg three times weekly appears safe and effective for CMV prophylaxis in SOT recipients requiring iHD, though it may be associated with an increased risk of thrombocytopenia. image
415.4: Real-world use of hypothermic machine perfusion: Trends and impact on short-term kidney allograft outcomes.
Cortez, Alexander, Tapia, Amanda, Benavides Lopez, Xiomara, Liang, Yun, Ryan, Randi , Nguyen, Michelle, Riad, Samy, Benavides, Xiomara , Ryan, Randi J. , Riad, Samy

Mayo Clinic

Transplantation | August 31, 2026 | Volume: 110 | Issue: 9S | Pages: No page available

10.1097/01.tp.0001251832.60643.8d Get It

Short‐Term Risk Stratification in Alcohol‐Associated Hepatitis: Small HDL Particles and Inflammation Vulnerability Index Values Improve Model for End‐Stage Liver Disease
Vilar‐Gómez, Eduardo , Connelly, Margery A. , Shah, Vijay H. , Shalaurova, Irina, Rafalko, Jill M. , Sanyal, Arun J. , Chalasani, Naga , Gawrieh, Samer , Chalasani, Naga , Sanyal, A J , Gawrieh, Samer , Vilar-Gomez, Eduardo

Mayo Clinic

Alcohol, Clinical and Experimental Research | August 10, 2026 | Volume: 50 | Issue: 8 | Pages: No page available

10.1111/acer.70388 | PMID 42572151 Get It

ABSTRACT Background Alcohol‐associated hepatitis (AH) has high short‐term mortality, whereas current prognostic models mainly reflect liver and renal dysfunction. The Metabolic Vulnerability Index (MVX) is a nuclear magnetic resonance‐derived score comprising the Inflammation Vulnerability Index (IVX; small high‐density lipoprotein particles [S‐HDL‐P] and GlycA) and the Metabolic Malnutrition Index (MMX). We evaluated whether MVX, IVX, and IVX components improve 90‐day mortality prediction beyond Model for End‐Stage Liver Disease (MELD) in AH. Methods Serum samples from 196 patients with AH, 169 heavy‐drinking controls, and 351 healthy controls were analyzed by nuclear magnetic resonance spectroscopy. The primary outcome was 90‐day AH‐related mortality. Biomarkers were modeled continuously after standardization within the AH cohort; S‐HDL‐P was modeled per 1 SD decrease. Cox models were adjusted for MELD, age, sex, white blood cell count, and baseline antibiotic or corticosteroid use. Model performance was assessed using Akaike information criterion (AIC), likelihood‐ratio testing, and Harrell's C ‐statistic. Results Among patients with AH, 30 AH‐related deaths occurred within 90 days (15.3%). IVX and MVX were highest in AH cases and increased with AH severity, whereas MMX did not consistently differentiate severity. Lower S‐HDL‐P was independently associated with 90‐day mortality in fully adjusted models (HR, 1.84; 95% CI, 1.01–3.35; p = 0.045), whereas GlycA was not (HR, 0.86; 95% CI, 0.54–1.37; p = 0.527). Adding S‐HDL‐P improved fully adjusted MELD‐based model fit (AIC, 298.97 vs. 301.46; LR p = 0.034; C ‐statistic, 0.741 vs. 0.729). IVX showed supportive improvement in model fit and discrimination (AIC, 299.81; LR p = 0.056; C ‐statistic, 0.749). Continuous MELD interaction analyses supported risk separation for S‐HDL‐P (LR χ 2 = 6.20; p = 0.045) and IVX (LR χ 2 = 6.64; p = 0.036). Conclusions Lower S‐HDL‐P appears to be the principal short‐term prognostic component within the IVX domain in AH. S‐HDL‐P and IVX may refine MELD‐based 90‐day risk stratification, pending external validation.
Quantitative single photon emission computed tomography/computed tomography of Tc-99m-pyrophosphate scans: metrics for short-term risk stratification in transthyretin cardiac amyloidosis
Pleasure, Mitchell , Jackson, Candace L. , DeLuca, Albert, Kinkhabwala, Mona, Liu, Qi, Chernovolenko, Margarita , Wats, Karan , Brailovsky, Yevgeniy, Maurer, Mathew S., Johnson, Lynne L. , Poterucha, Timothy J. , Einstein, Andrew Jeffrey , Castillo, Michelle , Kinkhabwala, Mona, Ruberg, Frederick L. , Elias, Pierre , Poterucha, Timothy Joseph

Mayo Clinic

Nuclear Medicine Communications | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mnm.0000000000002199 | PMID 42438950 Get It

Background Radionuclide SPECT/computed tomography (CT) is standard for diagnosing transthyretin cardiac amyloidosis (ATTR-CM), but the prognostic value of quantitative metrics remains incompletely defined. We investigated their prognostic utility and additive value beyond existing staging systems. Methods Retrospective study of patients undergoing technetium-99m-pyrophosphate (PYP) SPECT/CT, including consecutive clinically referred patients (October 2023 to 2024) and trial participants with positive scans from January 2022. Myocardial PYP was quantified using standardized uptake values (SUV mean and SUV max ) and volumetric measures [percent injected dose (%ID), cardiac amyloid activity (CAA)]. Major adverse cardiovascular events (MACEs) comprised heart failure hospitalization or death. Cox and Kaplan–Meier analyses assessed associations; likelihood ratio testing and change in area under the curve (AUC) evaluated the additive prognostic value to existing staging systems. Results Among 43 patients with ATTR-CM, 16 experienced MACE over a median 518 days. AUCs ranged from 0.74 to 0.88 at 3 months and 0.56–0.62 at 12 months. All variables trended toward association with MACE: SUV mean ( P = 0.02), SUV max ( P = 0.03), %ID ( P = 0.06), and CAA ( P = 0.06). After age adjustment, cut-points for SUV max (5.8) and SUV mean (3.5) remained associated with MACE. Adding imaging variables to the National Amyloidosis Centre and Columbia staging systems did not significantly improve prognostic accuracy (Δ χ 2 : 0.40–2.48, P = 0.11–0.53). Interobserver reproducibility was high (intraclass correlation coefficients = 0.89–0.99). Conclusion Quantitative Tc-99m–PYP SPECT/CT metrics were associated with short-term outcomes in ATTR-CM, but did not improve established staging systems. Findings are hypothesis-generating and require validation in larger cohorts.
Short-Term and Long-Term Opioid Prescribing by Specialty, 2010 to 2024
Heckmann, Rebekah, Ahadpour, Mitra , Hevesi, Sara A., Jeffery, Molly M., Buonora, Michele J. , Starrels, Joanna L. , Hevesi, Sara , Ross, Joseph S. , Jeffery, Molly Moore

Mayo Clinic

JAMA Network Open | July 7, 2026 | Volume: 9 | Issue: 7 | Pages: e2622016

10.1001/jamanetworkopen.2026.22016 | PMID 42412429 Get It

Importance Opioid prescribing has decreased in the US for more than a decade. However, less is known about how prescribing trends differ by prescriber specialty and separately for short-term and long-term opioid prescribing for which the indications, clinical decision-making, and potential for harm vary substantially. Objective To characterize opioid analgesic prescribing trends in the US between January 1, 2010, and December 31, 2024, by prescriber specialty, analyzing short-term and long-term opioid use episodes separately. Design, Setting, and Participants This cross-sectional study used administrative claims data for commercially insured and Medicare Advantage patients (aged ≥65 years and &amp;lt;65 years with long-term disability) with at least 90 days of enrollment in medical and prescription coverage. Statistical analysis was performed from May 2025 to September 2025. Main Outcomes and Measures Prescribing volume, daily dose, and prescription duration. Results The study identified 110 288 218 opioid fills by 14 959 612 patients during the 15-year study period. Among opioid fills, 59.4% were attributed to female patients; the median (IQR) age at opioid fill was 61 (50-71) years. From 2010 to 2024, decreases in opioid prescribing were greater for long-term than short-term opioid use episodes (eg, commercial cohort: 81.3% reduction [from 33.2 fills per 100-person years in 2010 to 6.2 in 2024] and 74.6% reduction [from 36.2 fills per 100-person years in 2010 to 9.2 in 2024]), respectively. The proportion of all opioid fills written by primary care clinicians decreased (eg, Medicare Advantage with disability cohort: from 52.2% to 47.2%), whereas those written by pain medicine specialists increased (eg, Medicare Advantage with disability cohort: from 17.1% to 25.7%). Distinct trends for short-term and long-term opioid use episodes were observed in prescription characteristics, such as daily dose and duration. Conclusions and Relevance In this cross-sectional study of opioid prescribing trends in the US between 2010 and 2024, decreases in prescribing were greatest in long-term opioid use episodes, and prescribing was increasingly concentrated among pain medicine specialists. These findings suggest the need to balance reductions in opioid prescribing with provision of nonopioid pain treatments and raise concerns about access to care for patients taking opioids for chronic pain management.
Short Leg Cast Versus Long Leg Cast Immobilization for Pediatric Tibia Fractures: A Systematic Review and Meta-Analysis
Sato, Alma , Khair, Yasmine J., Pashou, Angelica, Nasr, James, Bello, A. Yasmin B., Bulut, Halil , Abdelrahman, Rashad, Burns, James W F , Nakanishi, Hayato , Than, Christian A., Suresh, Sukrit, Lee, R Y, Than, Christian A. , Khair, Yousef , Than, Christian A , Khair, Yasmine J , Khair, Yasmine J.

Mayo Clinic

Journal of Pediatric Orthopaedics | June 19, 2026 | Volume: 46 | Issue: 8 | Pages: 503-510

10.1097/bpo.0000000000003374 | PMID 42318885 Get It

Background: Pediatric tibial fractures are common long-bone injuries, yet uncertainty remains in the optimal immobilization strategy. The comparative effectiveness and safety of short leg versus long leg casts in achieving stable healing and functional recovery have not been clearly established. Methods: A literature search was conducted across Medline, CINAHL, Embase, and Cochrane Library, from inception to August 2025, following PRISMA guidelines and registered with the International Prospective Register of Systematic Reviews (PROSPERO). Statistical analyses were performed using a random-effects model. Results: The initial search yielded 1236 studies; 6 studies with 413 pediatric patients met the inclusion criteria. A total of 163 underwent short leg casting (SLC) and 250 long leg casting (LLC). No differences were observed between SLC and LLC for coronal angulation (MD=0.12 degrees, 95% CI=−0.89 to 1.12, I 2 =58%) or sagittal angulation (MD=0.18 degrees, 95% CI=−0.71 to 1.07, I 2 =56%). Subgroup analyses showed no differences for tibial shaft fractures or Salter-Harris distal tibial fractures. Cast duration was similar between groups (MD=−0.74 wk, 95% CI=−1.49 to 0.01, I 2 =92%). Overall complication rates did not differ (OR=0.76, 95% CI=0.25 to 2.34, I 2 =0%), with no differences in Salter-Harris subgroup analysis (OR=0.67, 95% CI=0.05 to 9.91; I 2 =54%). SLC was associated with shorter time to weight-bearing (MD=−2.29, 95% CI=−4.49 to −0.08, I 2 =68%) and faster time to union (MD=−1.21, 95% CI=−2.16 to −0.25, I 2 =30%). Conclusion: SLCs may be considered as an alternative to LLCs in pediatric tibial shaft and distal tibial physeal fractures based on currently available retrospective comparative evidence. However, the evidence is limited by the retrospective design, clinical heterogeneity, and risk of confounding. Further prospective comparative studies are needed to define optimal indications for SLC use in this population. Level of Evidence: Level III, systematic review and meta-analysis of retrospective comparative studies.
Albumin–bilirubin index as a determinant of short- and long-term outcomes after locoregional therapy for hepatocellular carcinoma: A real-world propensity-matched analysis.
Tajiknia, Vida , Thukral, Jatin, Chandani, Kanishka Uttam, Gopu, Sooraj Srirangadhamu , Abdalla, Ahmad, Shah, Riya Kaushal, Thukral, Jatin, Nadeem, Ahmed

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16304 Get It

e16304 Background: Hepatic reserve is a critical determinant of outcomes in hepatocellular carcinoma (HCC), yet traditional scoring systems such as MELD are frequently unavailable or underpowered in real-world datasets. The albumin–bilirubin index (ALBI) is a validated, objective measure of liver function derived from routine laboratory values and has emerged as a pragmatic alternative for risk stratification. However, the impact of ALBI on longitudinal outcomes following locoregional therapy (LRT) for HCC in routine clinical practice remains incompletely characterized. Methods: We performed a retrospective cohort study using TriNetX to identify adults with HCC treated with locoregional therapies (transarterial chemoembolization, yttrium-90 radioembolization, stereotactic body radiation therapy, or thermal ablation). Hepatic reserve was assessed using an albumin–bilirubin–based definition with labs within 30 days pre-therapy. Low ALBI (preserved function) was defined as albumin ≥3.5 g/dL and bilirubin ≤2.0 mg/dL, and high ALBI (impaired function) as albumin < 3.5 g/dL or bilirubin > 2.0 mg/dL. Propensity score matching (1:1) balanced demographics and comorbidities. Outcomes at 6 months, 1, 3, and 5 years included mortality, hepatic failure, ascites, portal hypertension, and esophageal varices. RD, RR, OR, and HR with 95% CIs were reported. Results: After matching, 509 patients were included in each ALBI group. High ALBI was consistently associated with significantly worse outcomes across all time points. Overall mortality was higher in the high-ALBI group at 6 months (19.6% vs 8.7%), 1 year (31.0% vs 13.9%), 3 years (51.0% vs 28.3%), and 5 years (57.1% vs 35.6%). Corresponding hazard ratios for mortality ranged from 2.32 to 2.65 across time points (all p < 0.05). High ALBI was also associated with substantially increased risks of hepatic failure (5-year RD 23.9%, HR 3.29), ascites (5-year RD 18.5%, HR 2.50), and esophageal varices (5-year RD 8.5%, HR 2.60). These associations persisted from early through long-term follow-up, demonstrating durable prognostic separation by ALBI status. Conclusions: In this large, real-world cohort of HCC patients undergoing locoregional therapy, impaired hepatic reserve as defined by a high albumin–bilirubin index was strongly and consistently associated with worse short- and long-term survival and higher rates of hepatic decompensation. An albumin–bilirubin–based ALBI classification represents a pragmatic and clinically meaningful tool for risk stratification when MELD is unavailable and may inform treatment selection, prognostication, and post-therapy surveillance in routine clinical practice.